Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Gene |
RCV000494592 | SCV000582070 | uncertain significance | not provided | 2017-04-27 | criteria provided, single submitter | clinical testing | A novel variant of uncertain significance has been identified in the TTN gene. The c.3414 A>G variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to our knowledge. This variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. Although the c.3414 A>G variant results in a synonymous amino acid substitution (E1138E), in silico splice prediction programs predict this variant activates a cryptic splice donor site upstream of the natural donor site for intron 21 and may cause abnormal gene splicing, resulting in either an abnormal, truncated protein product or loss of protein from this allele through nonsense-mediated mRNA decay. However, c.3414 A>G is not located in the A-band region of titin, where the majority of pathogenic truncating variants associated with DCM have been reported (Herman D et al., 2012). In addition, other truncating TTN variants have been reported in approximately 3% of control alleles (Herman D et al., 2012). Furthermore, this substitution occurs at a nucleotide that is not conserved across species, and Guanine is the wild-type nucleotide at this position in multiple species. Therefore, based on the currently available information, it is unclear whether this variant is pathogenic or benign. |
| Ambry Genetics | RCV002446961 | SCV002612570 | likely benign | Cardiovascular phenotype | 2021-05-06 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |